SciSparc Ltd. (Nasdaq: SPRC) is a clinical-stage pharmaceutical company. In January 2026, the company completed a transformative acquisition of an IP portfolio for the MUSE™ single-use endoscopic system for GERD treatment, while its subsidiary NeuroThera Labs secured a new U.S. patent for antimicrobial-cannabinoid combinations.
Products
COMBINATION PLATFORMS CONSIST OF VARIOUS CANNABINOIDS AND N-ACYLETHANOLAMINES, CannAmide ™ Descriptoin: Repurposing previously approved compounds qualifies SciSparc to take advantage of the FDA’s 505 (b)(2) application protocol. SciSparc has built an intellectual property portfolio which currently comprises three granted U.S. patents and pending patent applications in six families, all focused on disorders of the central nervous system. Currently, drug candidates are designed to treat Tourette Syndrome, Autism Spectrum Disorder, Epilepsy, Obstructive Sleep Apnea, Alzheimer’s Disease and Agitation, and Pain. Research and development efforts are focused on creating a proprietary and unique combination of products, some available already in the market (CannAmide™), products in the accelerated regulatory path of 505 (b)(2) application (SCI-110, SCI-210) and products that constitute a new chemical entity (SCI-160).
